2023-07-272023-07-272020-10-01https://hdl.handle.net/20.500.14300/1172The House Committee on Oversight and Reform investigated Novartis International AG's actions regarding Gleevec, a drug used for treating chronic myeloid leukemia. The report, based on over 100,000 pages of internal documents, scrutinizes Novartis' pricing strategies, business practices, and efforts to minimize generic competition. The report underscores the broader issue of pharmaceutical price increases and the need for systemic reforms such as Medicare negotiation.46 pagesenStaff ReportsHouse Staff Report3: Health335: Prescription Drug Coverage and Costs116Yes